1 In
addition,
data are lacking with regard to the clinical responsiveness o
2 Because data are lacking for many species, most studies that model fu
3 m liver disease (cirrhosis + hepatocellular carcinoma),
but data are lacking at the local level (eg, county) to identify
4 d with future subclinical cardiovascular disease (CVD),
but data are lacking regarding CVD events or mortality.
5 ance in predicting in-hospital deterioration and death,
but data are lacking with respect to patient outcomes following i
6 ay contribute to indirect effects of rotavirus vaccine,
but data are lacking from low-income countries.
7 drugs are at high risk of venous thromboembolism (VTE),
but data are lacking from large prospective cohorts.
8 ch as DNA methylation underlie biological embedding,
causal data are lacking.
9 oducts have important differences, but comparative
clinical data are lacking.
10 onferring antimicrobial resistance in NG; however,
clinical data are lacking.
11 Prospective
clinical data are lacking.
12 Contemporary data are lacking regarding the prognosis and management of le
13 Current data are lacking for incidence, correlates, and prognosis ass
14 cies' potential range shifts, especially when more
detailed data are lacking on dispersal dynamics, demographic processes
15 (NETs) are thought to be rising, but updated
epidemiologic data are lacking.
16 ife-threatening emergency of which reliable
epidemiological data are lacking.
17 rophylaxis are rare complications for which
epidemiological data are lacking.
18 es have been associated with HLH but molecular
epidemiology data are lacking.
19 ollutants, including perchloroethylene (PERC),
experimental data are lacking, resulting in default assumptions being used
20 out the brain's fluid transport systems, where
experimental data are lacking, and what is still debated.
21 ethods for functional inference from comparative
expression data are lacking.
22 However,
data are lacking on long-term PPI use and cognitive function.
23 However,
data are lacking on the cardiovascular safety of degludec.
24 However,
data are lacking on the experience and impact of living with
25 shown improved short-term outcomes; however, long-term
HRQL data are lacking.
26 n the early origins of obesity, but intergenerational
human data are lacking.We prospectively investigated refined-grain
27 on is less well characterized, in part because
longitudinal data are lacking.
28 an immunodeficiency virus (HIV+ patients), but
longitudinal data are lacking.
29 ety data for diagnostic use have been positive,
multicenter data are lacking.
30 However, analysis methods that integrate both types
of data are lacking.
31 quencing, but direct comparisons between models and "
omics"
data are lacking.
32 reported hot flush severity, but underpinning
physiological data are lacking.
33 Although firm
prevalence data are lacking, there is a strong impression that food alle
34 g stereotactic body radiation therapy, although
prospective data are lacking.
35 ive chemoradiation over surgery alone, although
prospective data are lacking.
36 n-small cell lung cancer (NSCLC), but long-term
prospective data are lacking.
37 Reliable data are lacking on pregnancy outcomes during Ebola virus dis
38 dant sun exposure year-round, but nationally
representative data are lacking.
39 and computational tools for analyzing multi-modal CITE-
Seq data are lacking.
40 However,
similar data are lacking for the cellular response, which in gnathost
41 However,
such data are lacking and difficult to obtain for many populations
42 , effective approaches for the integrative analysis of
such data are lacking.
43 aria over time from large areas of the continent where
such data are lacking need to be prioritized.
44 d trials of 12 months' duration or less; however, long-
term data are lacking.
45 Further, performance assessments based on held-out
test data are lacking.
46 n who have sex with men (MSM), as routine universal
testing data are lacking.
47 Therefore,
data are lacking on the short- and long-term clinical outcome
48 s of mammalian steady-state metabolomic and
transcriptional data are lacking.
49 deration of aggregate exposures from all pathways and,
when data are lacking, the use of health-protective defaults.
50 after ablation for those at risk of stroke, but real-
world data are lacking.